Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Koshiya Tapped as Global Head of Oncology: Sumitomo Dainippon
March 23, 2017
- Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger
March 22, 2017
- US Biotech X-Chem Inks Collaboration Deals with Astellas, Ono
March 22, 2017
- Praluent Shows Consistent Efficacy, Safety in Diabetic and Non-Diabetic Patients: Japanese Subanalysis
March 22, 2017
- Ribomic Links Up with Astellas for Research on Development of Aptamer Therapy
March 22, 2017
- Hitachi Chemical to Buy US Cell Therapy Contract Manufacturer, Japan-Bound Operations Slated for FY2018
March 21, 2017
- Daiichi Sankyo, NIBIOHN Hook Up in Cancer Immunology with Mitsubishi Funding
March 17, 2017
- Novartis Vows Continued Reforms despite Not-Guilty Diovan Ruling
March 17, 2017
- Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
- Lilly to Continue Investment in Alzheimer’s after Solanezumab Setback: Japan Development Chief
March 16, 2017
- Lilly’s Japan Sales Keep Momentum in 2016 with 3.1% Rise
March 16, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Takeda Revving Up Partnership Initiatives
March 15, 2017
- Maruho Gets Global Rights to Toray’s RORγt Inhibitor
March 15, 2017
- Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
- Kissei, Maruishi Join Hands on Opioid Receptor Agonist
March 14, 2017
- INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
- Daiichi Sankyo Taps Heptares for Pain Med Discovery Research
March 14, 2017
- Daiichi Sankyo Launches Large-Scale Observational Study for Cancer VTE
March 14, 2017
- Toyama Chemical, Towa Settle Patent Suit over Ozex Pediatric Drug
March 14, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…